- Number of executions on sell side on semester: 609
- Traded volume on buy side on semester: 457,955 shares for € 1,916,480.01
- Traded volume on sell side on semester: 310,810 shares for € 1,312,111.94
• the following resources appeared on the liquidity account when the activity started:
- 0 shares
- € 500,000.00
The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.
About Nicox
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for
Nicox: Half-year liquidity contract statement with Kepler Cheuvreux
July 6, 2021 - release at 7:30 am CET
Sophia Antipolis, France
Under the liquidity contract entered into between NICOX and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2021:
- 218,919 shares
- Number of executions on sell side on semester: 1,298
- Traded volume on buy side on semester: 978,682 shares for € 4,245,529.01
- Traded volume on sell side on semester: 906,908 shares for € 3,977,929.37
As a reminder :
• the following resources appeared on the last half year statement on 31 December 2020 on the liquidity account:
- 147,145 shares
- Number of executions on sell side on semester: 609
® Agreement
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize ZERVIATE
® (cetirizine ophthalmic solution), 0.24% in the Chinese and the majority of South East Asian markets. Under the amended agreement, Ocumension will immediately pay Nicox $2 million in full advance payment of the future development and regulatory milestones for the product. Amendments were made to certain rights under non-financial clauses of the agreement.
Nicox remains eligible to receive the same sales milestones of up to US$17.2 million together with tiered royalties of between 5% and 9% of net sales of ZERVIATE by Ocumension. ZERVIATE is currently being evaluated in a confirmatory Phase 3 clinical trial in China by Ocumension, to support a Chinese New Drug Application for th
Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial
July 2nd, 2021 - release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase as well as the required two-week follow up period. Top-line results are expected to be announced in September 2021.
Mississippi trial
Phase 2
at Nicox,
amount
used to guide the future development of
NCX 4251
.
We will announce the next steps in the development of NCX 4251 following an End-of-Phase 2 meeting with the FDA.
Nicox s NCX 470 Demonstrates Significant Intraocular globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.